Synergy Pharmaceuticals Inc. (SGYP) Loss Submission Form

See If You Qualify For Monetary Reward

Levi & Korsinsky, LLP does not share your information with others. There is no cost or obligation for you to submit.

Submit Transaction Detail Now (Optional)

- OR -

    This submission does not create an attorney-client relationship. We will keep you up to date with this investigation, and should this investigation evolve, we will contact you to discuss whether to establish an attorney client relationship at no cost to you.

    FAX: 212-363-7171

    Levi & Korsinsky notifies investors that class action complaints have been filed on behalf of of Synergy Pharmaceuticals Inc. (“Synergy”) (NASDAQ: SGYP) shareholders who purchased shares between November 10, 2016 and November 14, 2017. You are hereby notified that securities class action lawsuits have been commenced in the USDC for the Eastern District of New York.

    The complaints allege that throughout the class periods Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) the loan from CRG Partners III L.P. (“CRG Loan”) did not fund Synergy’s operations through 2019; (2) the Company could not access the second tranche of $100 million financing on or before February 28, 2018 without issuing dilutive equity; and (3) the Company could not access the third tranche of the CRG Loan if and when needed because terms were required to be met in order to access those tranches.

    If you suffered a loss in Synergy you have until April 10, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.